Gilead Sciences, the youngest biopharmaceutical company on the ranking, was founded in 1987 in Foster City, CA. Gilead ranks #7 with a brand value of USD $13.361 billion.
The company’s mission is to advance the care of patients suffering from life-threatening diseases. The primary therapeutic areas of focus include HIV/AIDS, hepatitis B and C, hematology, oncology, cardiovascular disease, inflammation, and respiratory disease.
Gilead’s brand has a high degree of relevance among healthcare professionals (HCPs), who consistently acknowledge the company’s expertise in its core therapeutic areas. HCPs also highlight Gilead’s drive to address unmet medical needs through a relentless commitment to science and discovery research.
Gilead’s reputation for being at the forefront of cutting-edge research continues to grow with the company’s savvy acquisition of clinical leaders like Pharmasset. This acquisition, which cost Gilead USD $11 billion, resulted in the first curative therapies for hepatitis C. These bold plays in the market inspire HCPs to rank Gilead as exceeding expectations on the delivery of unique healthcare solutions. In addition, Gilead is being recognized for its legacy in HIV therapies and for offering valuable services and programs to patients that complement its leading therapies.